SUBSCRIBE
SUBSCRIBE
News   Business

AstraZeneca PLC to Further Develop Targacept, Inc.'s ADHD Drug; Targacept Eligible to Get Over $100 Million

July 8, 2009 | 
1 min read

Bookmark and Share

Reuters -- Targacept Inc said its licensing partner AstraZeneca agreed to pay $10 million milestone payment to further develop Targacept’s experimental treatment for attention deficit/hyperactivity disorder (ADHD).

Alliances
AstraZeneca Pharmaceuticals LP
MORE ON THIS TOPIC
Podcast
A Conversation With Kevin Marks, CEO of Delphia
March 4, 2025
 · 
1 min read
 · 
Annalee Armstrong
Contemporary art collage of hand holding a dart aiming at the target. Business targeting, aiming, focus concept. Modern design. Copy space.
NextGen
Delphia Eyes New Precision Medicine Approach: Activation Lethality
March 4, 2025
 · 
2 min read
 · 
Annalee Armstrong
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
CRISPR, Cytiva Laying Off Employees
March 3, 2025
 · 
139 min read
 · 
BioSpace Editorial Staff
AbbVie's office in South San Francisco, California
Obesity
Obesity Late-Comer AbbVie Inks Up to $2.2B Amylin Deal With Gubra
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac